Survival Trends in Pediatric Differentiated Thyroid Cancer: A Middle Eastern Perspective.

Middle Eastern children distant metastasis event-free survival lymph node metastasis pediatric thyroid cancer

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
22 Jan 2024
Historique:
received: 17 12 2023
revised: 16 01 2024
accepted: 19 01 2024
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

Pediatric Differentiated Thyroid Cancer (pedDTC) is a rare pediatric malignancy with an increasing incidence over time. To date, there is a paucity of literature specifically addressing pedDTC within the context of Middle Eastern ethnicity. This retrospective study aimed to assess the risk-stratifying factors for overall survival (OS) and event-free survival (EFS) in pediatric DTC patients from Iraq and Jordan. The medical records of 81 patients from two tertiary cancer institutes were retrieved. Kaplan-Meier analysis was employed to investigate OS and EFS, and the Cox proportional hazards model was employed to estimate hazard ratios. All patients underwent surgery and radioactive iodine therapy, with a median age of 14 and an interquartile range of 12-15. Lymph node involvement was observed in 55% of cases, while distant metastases were present in 13.5%. After a median follow-up period of 68 months, the 10-year survival rate was determined to be 94%, while the 10-year EFS rate was 58%. EFS was negatively impacted by cervical lymph node metastases and early age of diagnosis (

Identifiants

pubmed: 38276287
pii: life14010158
doi: 10.3390/life14010158
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Akram Al-Ibraheem (A)

Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
School of Medicine, University of Jordan, Amman 11942, Jordan.

Mohamed Al-Shammaa (M)

Department of Nuclear Medicine, Radiotherapy and Nuclear Medicine Hospital, Bab Al-Muadham, Baghdad 10047, Iraq.
Department of Nuclear Medicine, Al-Amal National Hospital, Al-Andalus Square, Baghdad 10069, Iraq.

Ahmed Saad Abdlkadir (AS)

Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Feras Istatieh (F)

Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Ula Al-Rasheed (U)

Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Thomas Pascual (T)

Philippine Nuclear Research Institute, Department of Science and Technology, Quezon City 1101, Philippines.

Rawad Rihani (R)

Department of Pediatrics, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Hadeel Halalsheh (H)

Department of Pediatrics, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Taleb Ismael (T)

Department of Pediatrics, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Aysar Khalaf (A)

Department of Nuclear Medicine, Warith International Cancer Institute, Karbala 56001, Iraq.

Iyad Sultan (I)

Department of Pediatrics, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Issa Mohamad (I)

Department of Radiation Oncology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Hikmat Abdel-Razeq (H)

Department of Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Asem Mansour (A)

Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.

Classifications MeSH